LaFleur & Godfrey LLC Sells 12,776 Shares of Hologic, Inc. (NASDAQ:HOLX)

LaFleur & Godfrey LLC lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 117,597 shares of the medical equipment provider's stock after selling 12,776 shares during the quarter. LaFleur & Godfrey LLC owned 0.05% of Hologic worth $7,264,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in shares of Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock valued at $412,159,000 after buying an additional 144,838 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Hologic by 0.5% during the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock valued at $354,506,000 after buying an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Hologic by 3.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after purchasing an additional 129,035 shares during the period. Invesco Ltd. raised its position in Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after purchasing an additional 572,187 shares during the period. Finally, Boston Partners raised its position in Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Activity

In related news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.88% of the company's stock.

Hologic Trading Down 0.2%

Shares of HOLX stock traded down $0.10 during mid-day trading on Friday, reaching $65.01. The stock had a trading volume of 3,320,131 shares, compared to its average volume of 2,371,550. The stock's 50-day moving average price is $60.00 and its two-hundred day moving average price is $64.06. The firm has a market capitalization of $14.49 billion, a PE ratio of 27.43, a price-to-earnings-growth ratio of 2.39 and a beta of 0.55. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.03 EPS. Equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Stephens decreased their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Citigroup decreased their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Royal Bank Of Canada decreased their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.